Appili Therapeutics Inc. (APLIF)
- Previous Close
0.0256 - Open
0.0260 - Bid --
- Ask --
- Day's Range
0.0251 - 0.0260 - 52 Week Range
0.0160 - 0.0760 - Volume
197,313 - Avg. Volume
226,011 - Market Cap (intraday)
3.601M - Beta (5Y Monthly) 1.14
- PE Ratio (TTM)
-- - EPS (TTM)
-0.0300 - Earnings Date Jun 21, 2024 - Jun 25, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
0.15
Appili Therapeutics Inc., a biopharmaceutical company, focuses on the acquisition and development of novel medicines for unmet needs in the infectious disease in Canada. Its anti-infective portfolio includes ATI-1501, a taste-masked liquid oral suspension formulation of an antibiotic, metronidazole; ATI-1801, a novel topical formulation of paromomycin for the treatment of cutaneous leishmaniasis; and ATI-1701 is a live-attenuated vaccine for Francisella tularensis. Appili Therapeutics Inc. was incorporated in 2015 and is headquartered in Halifax, Canada.
www.appilitherapeutics.comRecent News: APLIF
Performance Overview: APLIF
Trailing total returns as of 5/14/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: APLIF
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: APLIF
Valuation Measures
Market Cap
3.55M
Enterprise Value
8.96M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
3.69
Price/Book (mrq)
--
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-215.78%
Return on Equity (ttm)
--
Revenue (ttm)
1.15M
Net Income Avi to Common (ttm)
-5.34M
Diluted EPS (ttm)
-0.0300
Balance Sheet and Cash Flow
Total Cash (mrq)
602.88k
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-4.25M
Research Analysis: APLIF
Company Insights: APLIF
APLIF does not have Company Insights